In vitro, in vivo and stability assessment of optimised nanoparticulate matrix tablet of nebivolol hydrochloride
| Autor: | S. Nagargoje Sanjay, Punit R. Rachh, B. Pandhare Ramdas |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | International journal of health sciences. :6916-6937 |
| ISSN: | 2550-696X 2550-6978 |
| DOI: | 10.53730/ijhs.v6ns2.6733 |
| Popis: | The objective of the present study was to define the effects on the antihypertension activity and pharmacokinetics of an optimised nanoparticulate matrix tablet containing nebivolol hydrochloride. The nanoparticulate matrix tablet was formulated using Nebivolol nanoparticles which are prepared by a solvent evaporation method using varying concentrations of drug and polymer Eudragit RL 100 and optimised by two factorial designs using a quadratic model and the nanoparticulate matrix tablet was prepared by using a varying concentration of drug nanoparticles and ethyl cellulose. The sustained release ability formulation was further demonstrated in an in-vivo study in Wister rats. The prepared matrix tablets showed an improved bioavailability. The Tmax, Cmax, and the AUC were increased and extended, respectively. The antihypertensive activity showed a distinct change in SBP in DOCA salt-induced hypertensive rats as compared with pure drug. A significant reduction of DBP and HR were also observed after the treatment with nanoparticulate matrix tablet. There was no significant degradation and change in drug release rate in formulations during six months of stability testing. The results suggest that nanoparticulate matrix tablets can act as a promising carrier for nebivolol hydrochloride which offers an alternative approach for regular delivery of nebivolol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|